Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
The changes occurring in the pharmaceutical industry are redefining how innovations are imagined, constructed, and distributed. Focused on the rejuvenating combination of science, technology, and pharma, the changes create new models of cross-disciplinary collaboration for rapid advancements and betterment of the health of people.
Progress in the pharmaceutical industry was previously almost exclusively determined by the research conducted in laboratories. The focus has now shifted to innovation within an Integrated Approach to Innovation that encompasses the life sciences and the engineering, data sciences, and digital technology disciplines. The integration of these disciplines has fostered the development of more rapid, intelligent, and targeted processes for drug discovery and development.
The current pharmaceutical workforce comprises biologists, chemists, data scientists, software engineers, and almost every other specialized discipline that is required to address the complex challenges in healthcare.
The rapid advancement of technology, and more specifically artificial intelligence and machine learning, continues to significantly alter the drug discovery and development processes. The identification of drug candidates, molecular behavior prediction, clinical trial design, and every other aspect that was previously time intensive, can now occur almost instantly compared to the time it used to take.
The sharing and analysis of data and combining of technologies such as advanced imaging and automation allows for laboratories to make improvements and increases in precision and throughput. These technologies allow laboratories and researchers to conduct and make more experiments with more speed and accuracy.Robotic technology advances also provide laboratories to make improvements in the precision and throughput and to scale experiments to allow more tests and conduct more experiments.
Digital twin technology and simulation also allow scientists to replicate and predict outcomes of biological processes and systems without having to conduct an experiment. This technology allows the laboratory and researchers\ to mitigate and eliminate time, cost, and risk of the drug development process. Technological advances are changing the redefining and changing the processes of the drug development. From virtual compound screening to flexible, technology enabled and data driven clinical trials, every aspect of the life-cycle is incorporating technology in the laboratory.
Decentralized clinical trials, hybrid clinical trials, and continuous patient monitoring made possible by wearable technology and virtual monitoring, increase the involvement of patients, and improve the quality of the data captured. The integration of RWE data with clinical trial data provides more insight and increases the reporting of real effect of treatment.
Also, advanced analytics are enabling the implementation of adaptive clinical trials, which allow the real time revision of clinical trial objectives and procedures to improve the quality of patient outcomes.
The integration of multiple technological advancements has led to the development of personalized medicine. Through the combination of digital health tools, bioinformatics, and genomics, stakeholders and pharmaceutical companies are now able to create tailored medicines. This is particularly true in the case of oncology, rare diseases, and several chronic conditions, and where traditional methods usually do not work. Aside from enhancing positive results for patients, this change in the paradigm of medicine further enhances the value proposition of the therapies.
Innovative hubs combined with startups are essential for the development of this convergence. These lean, tech-oriented companies are leading radical shifts in the older paradigms of the pharmaceutical industry. Startups are leading the way with AI drug discovery platforms, digital therapeutics, and more.
Big pharma has multiple partnerships with these newcomers, be it through public-private partnerships, incubators, accelerators, and venture capital partnerships. Through this model, large companies can create value to stay competitive, and startups can scale their solutions.
Data, in today’s converged landscape, is of immense importance. The ability to provide valuable insights/innovations through the gathering, analyzing, and interpreting of extensive levels of biological and clinical data is what helps drive further advancements/innovations. The rapid analytical and interpretational ability of one organizational unit is not the case for those of data privacy, protection, and standardization.
Risk and trust mitigation through Customer Data Governance Platforms is an investment in reputation, and risk mitigation through data privacy protection services is sacrificing reputation/cost. Prevention through compliance structures is not an option.
The integration of technology, science, and pharmaceuticals presents unique opportunities and problems. It is not an easy task to integrate various systems, lead interdisciplinary teams, and integrate different cultural organizations. In addition, the rapid pace of technological change requires continuous retraining of employees. Organizations must provide the infrastructure necessary for employees to continue their education in order to keep pace with technological change. Regarding the rapid emergence of AI and digital therapeutics, there is a lack of clarity on the regulation of rapid technological change. To leverage the intertwined problems of Technology and the Workforce, the regulatory challenges must be resolved and optimized towards global convergence.
In the United States, the convergence of science, tech, and pharma is creating a more integrated and patient-centered future. The discrete fields of health system innovation are no longer distinct and are now characterized by a more whole systems approach. In this new era, the ability to change and the effective use of technology will be important. The businesses that lead this convergence will be the ones who radically change the industry and enhance the healthcare system.
The term “Beyond Boundaries” does not apply to merely an abstract idea, it embodies the emerging reality in the pharmaceutical industry. The new ecosystems in the pharmaceutical industry are limitless as a result of the integration of science and technology with pharmaceutical innovation The leaders of the industry clearly define the challenges. They need to remove the silos, and the barriers to industry crossovers and technological collaboration, and transform the potential of the industry into reality. Those leaders will determine the next set of innovations for the world by providing high quality, rapid, and efficient health care solutions.
